Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome.

Autor: Hartley SL; Waisman Center University of Wisconsin-Madison Madison Wisconsin USA.; Department of Human Development & Family Studies University of Wisconsin-Madison Madison Wisconsin USA., Handen BL; Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA., Devenny D; New York State Institute for Basic Research in Developmental Disabilities Albany New York USA., Tudorascu D; Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA., Piro-Gambetti B; Waisman Center University of Wisconsin-Madison Madison Wisconsin USA.; Department of Human Development & Family Studies University of Wisconsin-Madison Madison Wisconsin USA., Zammit MD; Waisman Center University of Wisconsin-Madison Madison Wisconsin USA.; Department of Medical Physics University of Wisconsin-Madison Madison Wisconsin USA., Laymon CM; Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA., Klunk WE; Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA., Zaman S; Department of Psychiatry University of Cambridge Cambridge UK., Cohen A; Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA., Christian BT; Waisman Center University of Wisconsin-Madison Madison Wisconsin USA.; Department of Medical Physics University of Wisconsin-Madison Madison Wisconsin USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (Amsterdam, Netherlands) [Alzheimers Dement (Amst)] 2020 Sep 13; Vol. 12 (1), pp. e12096. Date of Electronic Publication: 2020 Sep 13 (Print Publication: 2020).
DOI: 10.1002/dad2.12096
Abstrakt: Introduction: There is a critical need to identify measures of cognitive functioning sensitive to early Alzheimer's disease (AD) pathophysiology in Down syndrome to advance clinical trial research in this at-risk population. The objective of the study was to longitudinally track performance on cognitive measures in relation to neocortical and striatal amyloid beta (Aβ) in non-demented Down syndrome.
Methods: The study included 118 non-demented adults with Down syndrome who participated in two to five points of data collection, spanning 1.5 to 8 years. Episodic memory, visual attention and executive functioning, and motor planning and coordination were assessed. Aβ was measured via [C-11] Pittsburgh Compound-B (PiB) PET.
Results: PiB was associated with level and rate of decline in cognitive performance in episodic memory, visual attention, executive functioning, and visuospatial ability in models controlling for chronological age.
Discussion: The Cued Recall Test emerged as a promising indicator of transition from preclinical to prodromal AD.
Competing Interests: GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. William Klunk is a co‐inventor of PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. All other authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
(© 2020 the Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: